Protagenic Therapeutics, Inc.\new (PTIX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Mar 31
In fiscal 2026, Protagenic Therapeutics, Inc.\new reported revenue of $0. The company was profitable. It held $3.65M in total assets against $1.03M in total liabilities.
Key ratios (FY2026)
52.2%
Return on equity
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Operating Income | -$4.50M | -$2.59M | -$5.70M | -$4.53M | -$3.56M | -$4.14M | -$2.55M | -$2.09M | -$2.31M | -$2.37M |
| Net Income | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M |
| EPS (Diluted) | $0.59 | $-0.67 | $-1.13 | $-1.15 | $-0.82 | $-1.24 | — | — | — | — |
| Total Assets | $3.65M | $89.1K | $1.96M | $4.32M | $8.04M | $11.06M | $879.2K | $842.3K | $696.9K | $1.78M |
| Total Liabilities | $1.03M | $5.04M | $942.8K | $655.3K | $1.12M | $1.12M | $2.03M | $1.48M | $907.8K | — |
| Shareholders' Equity | $2.62M | -$4.95M | $1.01M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634.4K | -$210.9K | $1.22M |
| Cash & Equivalents | — | — | — | — | — | — | $671.1K | $798.6K | $362.5K | $399.7K |
| Operating Cash Flow | -$2.81M | -$1.77M | -$4.22M | -$3.70M | -$1.99M | -$2.80M | -$1.35M | -$488.0K | -$1.07M | -$1.38M |
| Capital Expenditures | $3.3K | — | — | $149.8K | $1.8K | — | — | — | — | — |
| Shares Outstanding | 1.81M | 5.80M | 7.24M | 4.44M | 4.32M | 4.30M | 10.36M | 10.26M | 10.26M | 10.26M |